{
    "id": 11802,
    "fullName": "RUFY2 - RET",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "RUFY2-RET results from the fusion of RUFY2 and RET (PMID: 25384085). RUFY2-RET has been identified in lung cancer (PMID: 25384085) and papillary thyroid carcinoma (PMID: 30466862), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 5909,
                    "pubMedId": 25384085,
                    "title": "Anchored multiplex PCR for targeted next-generation sequencing.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25384085"
                },
                {
                    "id": 16497,
                    "pubMedId": 30466862,
                    "title": "Novel rearrangements involving the RET gene in papillary thyroid carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30466862"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 55680,
        "geneSymbol": "RUFY2",
        "terms": [
            "RUFY2",
            "RABIP4R",
            "ZFYVE13"
        ]
    },
    "variant": "RUFY2 - RET",
    "createDate": "09/15/2015",
    "updateDate": "10/17/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 5979,
                "geneSymbol": "RET",
                "terms": [
                    "RET",
                    "CDHF12",
                    "CDHR16",
                    "HSCR1",
                    "MEN2A",
                    "MEN2B",
                    "MTC1",
                    "PTC",
                    "RET-ELE1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 16177,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, multikinase inhibitor treatment demonstrated suboptimal clinical efficacy in RET-rearranged non-small cell lung cancer patients with measurable baseline brain metastasis, with a confirmed intracranial response rate of 18% (2/11); Cometriq (cabozantinib) treatment resulted in no intracranial response in a patient harboring RUFY2-RET (PMID: 30017832).",
            "molecularProfile": {
                "id": 11899,
                "profileName": "RUFY2 - RET"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14285,
                    "pubMedId": 30017832,
                    "title": "Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30017832"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20708,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a RUFY2-RET fusion was detected in a non-small cell lung cancer patient harboring EGFR L858R with acquired resistance to Tagrisso (osimertinib) (PMID: 31911548).",
            "molecularProfile": {
                "id": 35297,
                "profileName": "RUFY2 - RET EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17999,
                    "pubMedId": 31911548,
                    "title": "Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911548"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 11899,
            "profileName": "RUFY2 - RET",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35297,
            "profileName": "RUFY2 - RET EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}